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Anxiety disorders are common and disabling chronic conditions 
(Nutt et al., 2002). Benzodiazepines are effective drugs (Baldwin 
et al., 2005) but their side effects (including sedation, develop-
ment of tolerance and withdrawal) preclude long term use 
(Baldwin et al., 2005; Nutt et al., 2002). Hence, antidepressants 
are first-line treatment for many anxiety disorders, but their onset 
of action is slow, taking weeks to produce an effect (Baldwin 
et al., 2005; Nutt et al., 2002). Therefore, there remains a need for 
fast acting anxiolytic agents which lack the unfavourable side 
effects characteristic of benzodiazepines.
The Translocator Protein (18kDa) (TSPO) has emerged as a 
potential drug target in the treatment of anxiety disorders 
(Rupprecht et al., 2010). It is expressed on the outer mitochondrial 
membrane (OMM) (Woods et al., 1996) of virtually all mamma-
lian cells, and found in highest density in steroidogenic cells 
(Gavish et al., 1999). Here, it is responsible for an early necessary 
step in the steroid synthesis pathway: the movement of cholesterol 
across the cytosolic side of the OMM, to the inner mitochondrial 
membrane (IMM) (Rone et al., 2009). This brings cholesterol into 
contact with a side chain cleavage enzyme in the IMM which 
converts it into pregnenolone, the precursor of all steroids. 
Pregnenolone subsequently proceeds down a specific synthetic 
pathway (dependent upon the cell type and hence the enzymes 
present) to yield the final steroid product. The movement of cho-
lesterol by TSPO is a necessary step in the formation of steroids, 
and if TSPO is experimentally silenced the rate of steroid synthe-
sis becomes negligible (Papadopoulos et al., 1997).
Steroid synthesis is not restricted to classically recognised 
steroidogenic tissue such as gonads and the adrenal gland, but in 
fact occurs within various other cells and tissues including those 
of the central nervous system (CNS) (Baulieu et al., 2001). Their 
products, neurosteroids, act at the level of gene expression but are 
also positive allosteric modulators of neurotransmitter receptors 
including γ-aminobutyric acid type A (GABAA) receptors 
(Rupprecht et al., 1999). Hence, as might be predicted, neuroster-
oids cause pronounced anxiolysis in animal models (Brot et al., 
1997; Carboni et al., 1996). This, and the observation that their 
concentrations are reduced during panic attacks in patients with 
panic disorder (Strohle et al., 2003), suggests that modulating the 
neurosteroid pathway may have therapeutic potential.
The TSPO is an attractive target for modulating the neuroster-
oid pathway because movement of cholesterol into the mitochon-
dria is thought to represent the rate limiting step in steroid 
synthesis (Figure 1) (Papadopoulos, 1993). Indeed, TSPO ligands 
have been shown to enhance neurosteroidogenesis in the brain and 
to exert acute anxiolytic activity in rodents (Verleye et al., 2005). 
The TSPO agonist, XBD173, has been investigated in healthy 
male volunteers using the cholecystokinin tetrapeptide (CCK4) 
challenge – a human model of panic-like anxiety (Strohle et al., 
2003). Subjects that showed a clear panic response to the neuro-
peptide CCK4 were randomised into one of five treatment arms 
(n=14 in each group) which consisted of seven days’ treatment 
with either placebo, the benzodiazepine alprazolam, or one of 
Stratified medicine in psychiatry:  
a worrying example or new opportunity  
in the treatment of anxiety?
David R Owen1, Rainer Rupprecht2 and David J Nutt1
Abstract
Stratified medicine is a new term that figures highly in current MRC and NHS strategy. It has developed from the earlier terms individualised or 
personalised medicine and refers to the use of genetic and/or endophenotypic measures to allow better targeting of treatments. The best exemplar 
is HER2 positivity in breast cancer to determine the efficacy of Herceptin. Clinical trials of this anti-cancer drug were initially unpromising, but once 
the HER2 positive subgroup was identified it was found, in this subgroup only, to be highly effective. It is presumed that similar subgroups will be 
found for many common disorders not just cancers, and that these will lead to much better targeted treatments. Such an advance may be necessary 
to develop new treatments in certain fields where the development of broad-spectrum/blockbuster treatments appears to have reached the end of the 
road; a particular example of this is in psychiatry. In this paper we discuss this issue in relation to psychiatry using a new and interesting example of 
how genotyping might help rescue an apparently failed novel treatment in anxiety disorders. 
Keywords
Stratified medicine, translocator protein, anxiety, neurosteroids
1 Neuropsychopharmacology Unit, Division of Experimental Medicine, 
Imperial College London, London, UK 
2 Department of Psychiatry and Psychotherapy, University Regensburg, 
Regensburg, Germany 
Corresponding author:
David Owen, Neuropsychopharmacology Unit, Division of Experimental 
Medicine, Imperial College London, Hammersmith Hospital, Du Cane 
Road, London, W12 ONN, UK. 
Email: d.owen@imperial.ac.uk
443746 JOP27210.1177/0269881112443746Owen et al.Journal of Psychopharmacology
2013
Perspectives
 at Universitatsbibliothek on August 25, 2016jop.sagepub.comDownloaded from 
120 Journal of Psychopharmacology 27(2)
three doses of XBD173 (10, 30 or 90 mg). A second CCK4 chal-
lenge was performed following the dosing period. At the highest 
dose, XBD173 attenuated CCK4-induced anxiety compared to 
placebo (p<0.036) to a degree similar in magnitude to the benzo-
diazepine (Rupprecht et al., 2009). However, whilst the TSPO 
agonist matched the benzodiazepine in terms of anxiolysis, the 
side effects reported were far fewer, and in fact similar to that 
reported in the placebo group. Whilst ~60% of subjects treated 
with the benzodiazepine complained of withdrawal symptoms 
such as sleep disturbances or restlessness, these side effects were 
rare in the TSPO agonist groups (Rupprecht et al., 2009).
On the basis of this encouraging study, a phase II trial was 
performed in patients with generalised anxiety disorder (GAD) 
comparing XBD173 versus placebo. In this unpublished study, 
XBD173 showed no reduction compared with placebo in a variety 
of anxiety measures.
How do we explain the lack of efficacy in the GAD trial given 
the success with the CCK4 challenge? The answer may lie in the 
choice of an inappropriate disease model – the CCK4 challenge 
resembles panic disorder much more closely than it does GAD. 
But perhaps more important was a failure to appreciate differ-
ences between patients regarding the way in which the drug inter-
acts with its target.
In early phase clinical trials there is an appropriate emphasis 
on pharmacokinetic differences between subjects. This is because 
the way in which the drug is absorbed, distributed, metabolised 
and excreted differs between subjects for various reasons includ-
ing comorbidity (e.g. age, renal or hepatic impairment) and con-
comitant medication (e.g. liver enzyme inducers and inhibitors). 
These pharmacokinetic differences mean that to achieve a certain 
concentration of the drug in the plasma, some patients require 
substantially larger doses than others. Conversely, however, there 
is an assumption that the occupancy of the drug target associated 
with a particular concentration of the drug remains relatively con-
stant between subjects. This is clearly an important assumption, 
because for most drugs the effect is mediated through occupation 
of a receptor, and the greater the occupation, the greater the effect. 
This assumption probably holds in most circumstances, because 
evolution would be expected to conserve the structure of impor-
tant molecules (i.e. those which make attractive drug targets). 
Hence, if the structure of the target is conserved across subjects, 
then the affinity with which the drug binds to it will also be con-
served, and so will the relationship between drug concentration 
and target occupancy.
Unfortunately, for the case of TSPO and the majority of drugs 
that bind it, positron emission tomography (PET) studies have 
Figure 1. XBD173: mechanism of action.
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revealed that this assumption is incorrect. As well as being an 
attractive drug target, TSPO is also an attractive target in PET 
because it is present in large numbers in microglia, the inflamma-
tory cell whose proliferation accompanies many diseases in the 
brain (Venneti et al., 2006). Quantifying TSPO, and thus micro-
glia, would be an extremely powerful research tool to understand 
the kinetics of neuroinflammation. However, TSPO PET studies 
in humans show unexpected variation in signal (Kreisl et al., 
2010), which was recently demonstrated to be due to variation in 
the affinity with which radioligands bind the TSPO (Owen et al., 
2010, 2011a). These binding affinity differences are determined by 
a single nucleotide polymorphism in the gene encoding the TSPO 
which causes a substitution of alanine to threonone at amino acid 
147 (A147T) (Owen et al., 2011c). This substitution changes the 
configuration of the binding site at which the majority of TSPO 
radioligands bind (Owen et al., 2011a, 2011c). Expression of this 
genetic variant is co-dominant: subjects either express two copies 
of the wildtype allele (AA), two copies of the mutant allele (TT), 
or are heterozygotes and express both wildtype and mutant copies 
of the TSPO in 50:50 proportion (AT) (Owen et al., 2011c). In 
Caucasians, the mutant allele (T) is common; 9% of the population 
are TT and 42% are AT (Owen et al., 2011c). In the Asian popula-
tion, however, the mutant allele is much less common; less than 
1% are AT and TT subjects are rarer still (Kurumaji et al., 2000).
As with the majority of TSPO radioligands, XBD173 binding 
is also affected by the A147T substitution – the polymorphism 
reduces XBD173 binding affinity to TSPO by a factor of roughly 
15-fold (Owen et al., 2011b) . This is highly relevant to the failed 
XBD173 GAD study, as the preceding XBD173 CCK4 study 
showed efficacy only at the highest dose of 90mg, with no effect 
seen at doses of 30mg and below (Rupprecht et al., 2009). The 
15-fold reduction in binding affinity means that the same dose 
will produce huge differences in TSPO occupancy between sub-
jects who differ with respect to the A147T substitution. For exam-
ple, if we arbitrarily assume that the highest dose of XBD173 
(90mg, which was sufficient to produce anxiolysis) causes TSPO 
occupancy of 50% in an AA subject, we can calculate that the 
lower dose (30mg, which did not produce an effect) would cause 
25% occupancy. In this example, therefore, efficacy is reached 
somewhere between 25 and 50% TSPO occupancy. However, for 
non-AA subjects, the reduction in binding affinity means that a 
90mg dose would cause TSPO occupancy of 12% in an AT subject 
and 6% in a TT subject. Hence the dose which is efficacious in AA 
subjects is sub-therapeutic in the rest of the population.
The clinical trial of XBD173 in GAD was performed in a 
chiefly Caucasian population. Because 50% of Caucasians express 
at least one copy of the mutant allele, this means that half of the 
subjects in the XBD173 arm of the study were in fact receiving a 
sub-therapeutic dose of the drug. In hindsight, therefore, the lack 
of efficacy ultimately found is unsurprising. Repeating the study 
with dosing appropriate to genotype may yield more promising 
results. An alternative approach would be to enrol only those sub-
jects likely to respond (i.e. AA subjects).
This recent example illustrates the importance of genotype in 
determining drug actions; moreover it shows how a clinical trial 
can be undermined by a lack of understanding of the target variabil-
ity. Examples in other branches of medicine exist too, such as the 
presence of 2D6 poor metabolisers, who benefit less from tramadol 
than extensive metabolisers, as tramadol is a pro-drug that requires 
metabolism for full efficacy (Poulsen et al., 1996). It is likely that 
there are many similar examples in psychiatry treatments that have 
yet to be discovered, and this should be a major focus for research. 
Regulators should now begin to develop effective and functional 
rules for this new approach to stratified medicines.
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